[go: up one dir, main page]

WO2018194280A1 - Procédé de détection de méthylation du gène syndécane 2 (sdc2) - Google Patents

Procédé de détection de méthylation du gène syndécane 2 (sdc2) Download PDF

Info

Publication number
WO2018194280A1
WO2018194280A1 PCT/KR2018/003415 KR2018003415W WO2018194280A1 WO 2018194280 A1 WO2018194280 A1 WO 2018194280A1 KR 2018003415 W KR2018003415 W KR 2018003415W WO 2018194280 A1 WO2018194280 A1 WO 2018194280A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
dna
seq
methylation
sdc2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/003415
Other languages
English (en)
Korean (ko)
Inventor
안성환
오태정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomictree Inc
Original Assignee
Genomictree Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomictree Inc filed Critical Genomictree Inc
Publication of WO2018194280A1 publication Critical patent/WO2018194280A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Definitions

  • the present invention relates to a method for detecting CpG islet methylation of SDC2 gene, a composition for detecting CpG islet methylation of SDC2 gene, and a kit for detecting CpG islet methylation of SDC2 gene.
  • Method for amplifying methylated SDC2 DNA using forward and / or reverse primer comprising CG or GC to detect CpG island region methylation of SDC2 gene, Composition for detecting CpG island region methylation of SDC2 gene comprising said primer It relates to a kit for detecting the CpG island region methylation of the SDC2 gene comprising the primer.
  • the genomic DNA of mammalian cells contains a fifth base in addition to A, C, G, and T, which is 5-methylcytosine (5-mC) having a methyl group attached to the fifth carbon of the cytosine ring.
  • 5-mC always appears in C of CG dinucleotides (5'-mCG-3 '), and this CG is often referred to as CpG.
  • Most of C of CpG is methylated because a methyl group is attached. This methylation of CpG inhibits the expression of repetitive sequences in the genome, such as Alu or transposon, and is the site where extragenic changes occur most frequently in mammalian cells.
  • CpG islands There are exceptionally densely packed CpGs, which are called CpG islands.
  • CpG islands are 0.2 ⁇ 3kb in length, the distribution percentage of C and G bases is over 50%, and the distribution percentage of CpG is more than 3.75%.
  • About 45,000 CpG islands appear in the entire human genome, particularly in promoter regions that regulate gene expression. Indeed, CpG islands appear in promoters of housekeeping genes, which make up about half of human genes (Cross, S. et al., Curr. Opin. Gene Develop ., 5: 309, 1995).
  • Abnormal DNA methylation is known to occur mainly in the 5 'regulatory region of the gene, thereby reducing the expression of the gene.
  • the 5 'expression control region of the gene includes a promoter, an enhancer, and a 5'-untranslated region.
  • attempts have been actively made to examine methylation of 5 'expression-regulated sites of tumor-related genes in blood, sputum, saliva, feces, and urine, and to use them for diagnosis of various cancers.
  • DNA leaked by processes such as apoptosis or necrosis flows into the blood, and methylated DNA fragments are also present in cell-free tumor DNA in serum or plasma. It is known that these abnormally present DNA methylation fragments are used as targets for cancer diagnosis.
  • tumor cells are exfoliated and fall out in the form of body fluids such as feces, urine, sputum, and bronchial lavage fluid, the methylation of DNA in cells present in them is used as a target for diagnosing cancer.
  • the SDC2 (syndecane-2) gene is a gene involved in cell migration, differentiation and proliferation, and was first identified by the inventors of the methylation in colorectal cancer (Oh et al., J. Mol. Diag. 2013).
  • Candidate genes hypermethylated in colorectal cancer tissues compared to normal tissues by separating methylated DNA from colorectal cancer tissues and normal tissue DNAs of 12 colorectal cancer patients from stage I to stage IV through DNA microarray analysis Excavated them. After a series of validation procedures, SDC2 was identified as a promising methylation biomarker for early diagnosis of colorectal cancer.
  • the inventors of the present application can efficiently methylate SDC2 (Syndecan 2) gene CpG island region with high sensitivity and accuracy when using complementary binding to methylated SDC2 DNA and comprising one or more CG. It was confirmed that it can detect, and the present invention was completed.
  • the main object of the present invention is to provide a method for effectively detecting the CpG island region methylation of SDC2 (Syndecan 2) gene.
  • Another object of the present invention is to provide a composition and kit for detecting methylation of CpG island region of SDC2 gene.
  • the present invention comprises the steps of (a) processing a reagent for differently modifying the methylated DNA and unmethylated DNA in the DNA isolated from the clinical sample; (b) amplifying methylated SDC2 DNA using forward and / or reverse primers complementarily binding to methylated SDC2 DNA and comprising one or more CpG dinucleotides; And (c) provides a method for detecting the methylation of the CpG island region of the SDC2 (Syndecan 2) gene comprising the step of confirming the production of the product amplified by the primer.
  • the present invention also provides a composition for detecting methylation of a CpG island region of an SDC2 gene comprising a forward and / or reverse primer comprising at least one CpG dinucleotide, which can complement and amplify methylated SDC2 DNA. do.
  • the present invention furthermore detects methylation of the CpG island region of the SDC2 (Syndecan 2) gene comprising forward and / or reverse primers that can complement and amplify methylated SDC2 DNA and comprise one or more CpG dinucleotides.
  • SDC2 SDC2
  • 1 is a schematic of the detection rate of detecting SDC2 gene methylation in a variety of specimens using 808 sets of primers and probes used in the method according to the present invention.
  • Figure 2 is a measure of the degree of methylation of the SDC2 gene in stool samples of normal and colorectal cancer patients using the 808 sets of primers and probes used in the method according to the present invention.
  • Figure 3 measures the methylation of the SDC2 gene in serum samples of normal and colorectal cancer patients using the 808 sets of primers and probes used in the method according to the present invention.
  • the present invention relates to a method for detecting methylation of an SDC2 (Syndecan 2) gene CpG island region comprising the following steps:
  • Methods of the present invention means that the methyl group attached to the fifth carbon of the cytosine (cytocine) base ring is modified to 5-methylcytosine (5-mC), 5-methylcytosine is always C only of CG dinucleotide (5'-mCG-3 '), this CG is often referred to as CpG.
  • This methylation of CpG inhibits the expression of repeating sequences in the genome, such as alu and transposon, and is the site where extragenic changes occur most frequently in mammalian cells.
  • CpG islands there are exceptionally dense ones, which are called CpG islands.
  • CpG islands are 0.2-3kb in length, and the distribution percentage of C and G bases is over 50%, and the distribution percentage of CpG is concentrated to 3.75% or more.
  • About 45,000 CpG islands appear in the entire human genome, particularly in promoter regions that regulate gene expression. Indeed, CpG islands appear in the promoters of housekeeping genes, which make up about half of human genes.
  • the presence of CpG methylation in the target DNA can be indicative of disease, for example measuring the CpG methylation of any one of a promoter, 5 ′ untranslated region, intron and exon of the target DNA.
  • CpG-containing genes are typically DNA.
  • the method of the present invention may apply for example a sample containing DNA or RNA comprising DNA and mRNA, wherein the DNA or RNA may be single stranded or double stranded, or DNA-RNA hybrids may be used. It may be characterized by the contained sample.
  • Nucleic acid mixtures may also be used.
  • “multiple” includes both cases where there are a plurality of specific nucleic acid sequence sites to be detected in a kind of gene and a case where a plurality of target DNAs are included in one tube (single reactor).
  • the specific nucleic acid sequence to be detected may be a fraction of a large molecule, and from the outset the specific sequence may exist in the form of isolated molecules that make up the entire nucleic acid sequence.
  • the nucleic acid sequence need not be nucleic acid present in pure form, and the nucleic acid may be a small fraction in a complex mixture, such as containing whole human DNA.
  • the present invention is to detect the methylation of a plurality of target DNA in a sample in a single reactor
  • the sample may include a plurality of multiple target DNA, the target DNA, as well as the control gene, abnormally methylated expression
  • any gene that affects the development or progression of cancer can be used without limitation.
  • the sample may be derived from the human body, for example, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, gastric cancer, breast cancer, metastatic cancer, prostate Cancer, pancreatic cancer or lung cancer patients may be derived, and the sample may use solid or liquid tissue, cells, feces, urine, blood, serum or plasma.
  • sample includes a wide range of all biological fluids obtained from an individual, body fluid, cell line, tissue culture, etc., depending on the type of assay being performed, for example, Cells, tissues, biopsies, paraffin tissue, and microneedle aspirates may also be included, including feces, blood, serum, plasma, and urine, and flowed out of the lavage of cells, feces, urine, sputum, and bronchi.
  • the clinical sample may be used to wash tissue, biopsy, paraffin tissue, feces, blood, serum, plasma, microneedle aspirate, urine, cells, feces, urine, sputum and bronchus, for example, from a suspected cancer patient or a diagnosis target. It may be selected from the group consisting of cells flowed out of one wash solution and combinations thereof, but is not limited thereto. It is popularly known as.
  • DNA is separated from the clinical sample, and DNA separation may be performed by inducing magnetic particles to bind with DNA in clinical samples, for example, using magnetic particles, and then applying an external magnetic field to the specimen.
  • Magnetic particles used for DNA separation may have a particle size of about 50-2000 nm. Separation of DNA from the clinical sample may be performed using any one of various DNA separation kits or similar DNA separation reagents that are commercially available.
  • reagents that are bisulfite, hydrogen sulfite, disulfite, or a combination thereof can be treated to modify the methylated and unmethylated DNA differently.
  • the genomic DNA sequence of the CpG island region where methylation may occur in the SDC2 gene is shown in SEQ ID NO: 1, and the reagent for modifying the DNA sequence differently from methylated DNA and unmethylated DNA, for example,
  • the cytosine bases methylated by the reagent are not converted, and the unmethylated cytosine bases can be converted to bases other than uracil or cytosine.
  • the nucleotide sequence corresponding to the methylated SDC2 DNA is shown in SEQ ID NO: 2.
  • primers are, for example, 10mer to 40mer oligonucleotides capable of complementarily binding to methylated SDC2 DNA to amplify methylated SDC2 DNA, wherein the primers are "substituted" with each strand of the locus to be amplified in the target DNA. It can be manufactured to have complementarity. This means that the primers have sufficient complementarity to hybridize with the corresponding nucleic acid strands under the conditions for carrying out the polymerization.
  • the primers comprise forward and / or reverse primers, and the forward and / or reverse primers comprise one or more CG or GC.
  • the forward primer may bind to a sequence complementary to the sequence of SEQ ID NO: 2 to specifically amplify a sequence complementary to the sequence of SEQ ID NO: 2, and may include cytosine (C) at the 3 'end.
  • C cytosine
  • the sequence of converting the methylated sense strand of the SDC2 gene into bisulfite is described in SEQ ID NO: 2
  • the forward primer binds to a sequence complementary to the sequence of SEQ ID NO: 2, at the 3 'end. It can be designed to further distinguish between methylated (“C”) and unmethylated (“U", "T”) SDC2 genes by ending with "C” in CG.
  • the reverse primer may bind to the sequence of SEQ ID NO: 2, amplify the sequence of SEQ ID NO: 2, and include guanine (G) at the 3 'end.
  • it may be designed to bind complementary to SEQ ID NO: 2 and to make guanine (G) at the 3 'end by directing the orientation of the primer to the opposite of the forward primer.
  • the reverse primer primarily binds to the template of SEQ ID NO: 2, and amplification occurs. At this time, the forward primer is secondarily bound to the amplified sequence, thereby enabling amplification.
  • the primer may include a pair of primers including forward and reverse primers.
  • the primers may be, for example, SEQ ID NOs: 3, 4, 6-67, 69-100, 102-153, 155-216, 218-279, 281-342, 344-395, 397-448, 450 At least 80% homology with one or more sequences selected from the group consisting of -511, 513-574, 576-637, 639-700, 702-763, 765-826, 828-841, specifically 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% It may include a sequence showing the above homology, but is not limited thereto.
  • the primers may be selected from the group consisting of CH 3 (methyl), -OCH 3, -NH 2, -F (fluorine), -O-2-methoxyethyl -O-propyl, By substitution with -O-2-methylthioethyl, -O-3-aminopropyl, -O-3-dimethylaminopropyl, -ON-methylacetamido or -O-dimethylamidooxyethyl transform; Modification in which oxygen in a sugar structure in nucleotides is replaced with sulfur; Modification of internucleotide linkages to phosphorothioate or boranophosphophate, methyl phosphonate linkages, or combinations of one or two or more, or combinations of peptide nucleic acid (PNA), LNA nucleotides modified in the form of (locked nucleic acid), UNA (unlocked nucleic acid) or inosine; It may include one or more nucleotides modified in
  • Said primers are for example SEQ ID NOs: 3, 4, 6-67, 69-100, 102-153, 155-216, 218-279, 281-342, 344-395, 397-448, 450-511, 513
  • the primer may include, for example, the forward and reverse primers described in Table 2.
  • the method may include detecting methylation of the target DNA using a self-reporting function or using an energy transfer labeled primer.
  • self-reporting as used herein is often referred to as an "energy transfer label" and may be used interchangeably herein.
  • a universal primer having a self-reporting function may be mixed with an energy transfer labeled primer.
  • Self-reporting or energy transfer labeling function does not fluoresce by self-quenching at a stage where amplification does not occur, but self-quenching or self probing (self-quenching) where quenching is released when amplification occurs.
  • -probing Nazarenko IA et al., Nulceic Acid Res, 1997, 25 (12): 2516-2521; Whitcombe D et al., Nat Biotechnol , 1999, 17 (8): 804- 807; Myakishev MV et al., Genome Res , 2001, 11: 163-169; Nazarenko IA et al., Nucleic Acid Res , 2002, 30 (9): 2089-2195; Bengra C et al., Clin Chem, 2002 , 48 (12): 2131-2140; Murray JL et al., J Mol Diag, 2014, 16 (6): 627-638; Gao L et al., Mol Cell Probes , 2015, 29
  • it may further include a probe capable of hybridizing with the methylated SDC2 DNA to determine whether a product amplified with a primer is present.
  • the methylation may be, for example, PCR, methylation specific PCR, real time methylation specific PCR, PCR using methylated DNA specific binding antibody or aptamer, quantitative PCR, nucleic acid chip, sequencing,
  • the method may be performed by a method selected from the group consisting of sequencing by synthesis and sequencing by ligation, but is not limited thereto.
  • Methylation specific PCR When detected by the methylation specific PCR, bisulfite treatment results in cytosine at the 5'-CpG'-3 site as it is methylated, and remains unmethylated. If so, it turns into uracil. Therefore, a primer corresponding to the site where the 5'-CpG-3 'nucleotide sequence exists can be prepared for the converted nucleotide sequence after bisulfite treatment. When PCR is carried out using a primer, the PCR product is made from the primer corresponding to the methylated nucleotide sequence, and methylation can be confirmed by agarose gel electrophoresis.
  • the methylation detection probe may be a TaqMan, a Molecular Beacon, a probe having a self-reporting function or an energy transfer labeling function, but is not limited thereto.
  • Real time methylation specific PCR (real time methylation specific PCR):
  • the real time methylation specific PCR is a conversion of the methylation specific PCR method to a real-time measurement method, in the case of methylation after treating bisulfite to genomic DNA
  • the PCR primers are designed and real-time PCR is performed using these primers.
  • real-time methylation specific PCR can selectively quantitate only methylated DNA.
  • a standard curve may be prepared using an in vitro methylated DNA sample, and for standardization, a gene without a 5'-CpG-3 'sequence in the base sequence may be amplified with a negative control to quantitatively analyze the degree of methylation.
  • the real-time methylation-specific PCR is a conversion of the methylation-specific PCR method to a real-time measurement method, after treating bisulfite in the genomic DNA, designing a methylation independent PCR primers, these primers To perform real-time PCR using.
  • the amplified nucleotide sequence includes both methylated and unmethylated DNA, and there is a method of detecting using a probe capable of complementarily binding to methylated DNA.
  • real-time methylation specific PCR can selectively quantitate only methylated DNA.
  • Another method of detecting nucleic acid containing methylated CpG comprises contacting a sample containing nucleic acid with an agent that modifies unmethylated cytosine and a CpG-specific oligonucleotide Amplifying the CpG-containing nucleic acid of the sample using a primer.
  • the oligonucleotide primer may be characterized by detecting the methylated nucleic acid by distinguishing the modified methylated and unmethylated nucleic acid.
  • the amplification step is optional and desirable but not necessary.
  • the method relies on a PCR reaction that distinguishes between modified (eg, chemically modified) methylated and unmethylated DNA.
  • Bisulfite sequencing method Another method for detecting nucleic acid containing methylated CpG is contacting a sample containing nucleic acid with an agent that modifies non-methylated cytosine and methylation independent oligonucleotide primer. Amplifying the CpG-containing nucleic acid in the sample.
  • the oligonucleotide primer may be characterized by amplifying the nucleic acid without distinguishing the modified methylated and unmethylated nucleic acid.
  • the amplified products have been described in connection with bisulfite sequencing for the detection of methylated nucleic acids by sequencing by Sanger method using sequencing primers or by next generation sequencing method.
  • next generation sequencing method may be characterized by sequencing by synthesis and sequencing by ligation.
  • the unique feature of this method is that instead of producing bacterial clones, a single DNA fragment is spatially separated, amplified in situ, and sequenced. In this case, since several hundreds of thousands of fragments are read at the same time, it is also called a massively parallel sequencing method.
  • a sequencing by synthesis method and a method of obtaining a signal by attaching mono or dinucleotides sequentially includes pyro sequencing, ion torrent, and Solexa methods.
  • NGS equipment based on sequencing by synthesis includes Roche's 454 platform, Illumina's HiSeq platform, Life Technology's Ion PGM platform, and finally PacBio platform on Pacific BioSciences. have. 454 and Ion PGM use emersion PCR as a clonal amplification method, and HiSeq uses bridge amplification.
  • the sequencing by synthesis method reads a sequence by detecting phosphate, hydrogen ions, or pre-attached fluorescence generated when DNA is synthesized by sequentially attaching one nucleotide.
  • 454 uses a pyroseqeuncing method using phosphoric acid
  • Ion PGM uses hydrogen ion detection.
  • Sequencing by ligation is a sequencing technique that uses DNA ligase to identify nucleotides at specific positions in the DNA sequence. Unlike most sequencing techniques that use polymerases, they do not use polymerases and take advantage of the feature that DNA ligase does not ligation mismatch sequences. This is the case with SOLiD systems. In this technique, two bases are read at intervals, which are repeated five times independently through a primer reset, so that each base is read twice twice to increase accuracy.
  • dinucleotide primers corresponding to the corresponding sequencing are sequentially ligated, and the combination of these ligations is analyzed and finally The base sequence of the DNA is completed.
  • next generation sequencing method may be characterized by a sequencing by synthesis or a sequencing by ligation method.
  • the product amplified by the primer may be used as a probe without limitation as long as it can hybridize with the target DNA and detect methylation, for example, but may include, for example, one or more CpG dinucleotides, or the probe may include SEQ ID NOs: 5 and 68 At least 80% homology with one or more sequences selected from the group consisting of 101, 154, 217, 280, 343, 396, 449, 512, 575, 638, 701, 764, 827 and 842, specifically 81%, 82 %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, It may include, but is not limited to, sequences that exhibit 99% or more homology.
  • the probe may comprise one or more sequences selected from the group consisting of SEQ ID NOs: 5, 68, 101, 154, 217, 280, 343, 396, 449, 512, 575, 638, 701, 764, 827 and 842. .
  • the probe may include, for example, the probes described in Table 2.
  • the reverse primer When the reverse primer is primarily bound to the template of SEQ ID NO: 2, amplification occurs. At this time, the forward primer and the probe are secondarily bound to the amplified sequence, whereby amplification proceeds to release a signal by a probe or fluorescent dye. Can be.
  • nucleic acid hybridization (hybridization) reactions the conditions used to achieve stringent specific levels vary depending on the nature of the nucleic acid being hybridized. For example, the length of the nucleic acid region to be hybridized, degree of homology, nucleotide sequence composition (eg, GC / AT composition ratio), and nucleic acid type (eg, RNA, DNA) select hybridization conditions. Is considered. Further considerations are whether the nucleic acid is immobilized, for example, in a filter or the like.
  • Examples of very stringent conditions are as follows: 2X SSC / 0.1% SDS at room temperature (hybridization conditions); 0.2X SSC / 0.1% SDS at room temperature (low stringency conditions); 0.2X SSC / 0.1% SDS at 42 ° C. (conditions with moderate stringency); 0.1X SSC at 68 ° C. conditions with high stringency.
  • the washing process can be carried out using one of these conditions, for example a condition with high stringency, or each of the above conditions, each of 10-15 minutes in the order described above, all or all of the conditions described above. Some iterations can be done. However, as described above, the optimum conditions vary with the particular hybridization reaction involved and can be determined experimentally. In general, conditions of high stringency are used for hybridization of critical probes.
  • the probe may be characterized in that the reporter (quencher) or the reporter (quencher) is coupled to the sock end, the reporter is FAM (6-carboxyfluorescein), Texas red, HEX (2 ', 4 ', 5', 7'-tetrachloro-6-carboxy-4,7-dichlorofluorescein), JOE, CY3 and CY5 may be one or more selected from the group consisting of, the quencher TAMRA (6- carboxytetramethyl-rhodamine), BHQ1, BHQ2 and Dabcyl can be characterized in that at least one selected from the group consisting of.
  • composition for detecting methylation of the CpG island region of the SDC2 gene comprising a forward and / or reverse primer comprising at least one CpG dinucleotide and can amplify by binding to a methylated SDC2 DNA It is about.
  • composition according to the invention the description of the composition overlapping with the composition in the method described above applies equally.
  • the present invention provides a method for binding to amplified methylated SDC2 DNA and complementing the CpG island region of an SDC2 (Syndecan 2) gene comprising forward and / or reverse primers comprising at least one CpG dinucleotide. It relates to a kit for detecting methylation.
  • the kit may comprise a compartment containing carrier means for containing a sample, a container comprising a reagent, a container comprising a primer capable of amplifying the methylated SDC2 gene.
  • a container comprising a probe capable of amplifying the methylated SDC2 gene.
  • it may also include a container containing a probe for detecting the amplification product.
  • the carrier means is suitable for containing one or more containers, such as bottles, tubes, each container containing independent components used in the method of the invention.
  • containers such as bottles, tubes
  • each container containing independent components used in the method of the invention.
  • one of ordinary skill in the art can readily dispense the required formulation in the container.
  • EpiTect PCR Control DNA set (Qiagen, Cat. No. 59695) was used to test the ability of these primers and probes to detect SDC2 gene methylation.
  • the EpiTect PCR Control DNA set is a DNA set that converts methylated and unmethylated human genomic DNA into bisulfite.
  • Methylation specific real time PCR (qMSP) was performed using the 808 sets of methylation specific primers and probes using these genomic DNAs.
  • qMSP Rotor-Gene Q PCR equipment (Qiagen). 20 ⁇ l total PCR reaction solution (template DNA, 2 ⁇ l; 5X AptaTaq DNA Master (Roche Diagnostics), 4 ⁇ l; PCR primer, 2 ⁇ l (2 pmole / ⁇ l), TaqMan probe, 2 ⁇ l (2 pmole / ⁇ l); DW 10 ⁇ l) was prepared, and PCR conditions were performed 40 times with 95 ° C. for 5 minutes, 15 seconds at 95 ° C., and 1 minute at an annealing temperature. PCR product amplification was confirmed by measuring the cycle threshold (CT) value. SDC2 gene methylation degree of each primer and probe pair was measured by CT value. If CT value is detected in methylated genomic DNA, methylation is detected normally. Determined. It was confirmed that methylation of the SDC2 gene was normally detected in all 808 sets of primers and probes tested (Table 2).
  • CT cycle threshold
  • FIG. 1 shows an amplification curve of qMSP using 12 sets of primers and probes as an example of 808 sets.
  • the amplification curve is shown in methylated DNA, but amplified in non-methylated DNA and distilled water (DW) as a template. You can see that the curve does not appear at all.
  • DW distilled water
  • Stool DNA showed a detection rate of 100% from 20 ng to 0.1 ng and 96%, 92% and 54% at 0.05 ng, 0.02 ng and 0.01 ng, respectively.
  • the detection rate was 100% from 20 ng to 0.1 ng and 96%, 71% and 33% at 0.05 ng, 0.02 ng and 0.01 ng, respectively.
  • SDC2 gene methylation can be detected in various samples such as cell lines, feces and serum.
  • SDC2 gene methylation detection primers and probes were used to reconfirm the ability to detect SDC2 gene methylation in various samples. For this, set 808 was selected as the best CT value of 23.7 in methylated DNA in methylation assay using methylated and unmethylated DNA.
  • genomic DNA was isolated from 47 stool patients and 16 normal stool patients. The isolated genomic DNA, 2.0 ug, was converted to bisulfite using the EZ DNA Methylation Gold kit (Zymo Research) according to the manufacturer's instructions and eluted with final 10 uL of distilled water.
  • Methylation specific real time PCR was performed using the set 808 methylation specific primers and probes using these genomic DNAs.
  • qMSP was used Rotor-Gene Q PCR equipment (Qiagen).
  • 20 ⁇ l total PCR reaction solution (template DNA, 2 ⁇ l; 5X AptaTaq DNA Master (Roche Diagnostics), 4 ⁇ l; PCR primer, 2 ⁇ l (2 pmole / ⁇ l), TaqMan probe, 2 ⁇ l (2 pmole / ⁇ l); DW 10 ⁇ l) was prepared and PCR conditions were performed 40 times with 95 ° C. for 5 minutes, 15 seconds at 95 ° C., and 1 minute at 60 ° C. annealing temperature. Amplification of the PCR product was confirmed by measuring a cycle threshold (CT) value.
  • CT cycle threshold
  • CT values were used to assess the sensitivity and specificity for the diagnosis of colorectal cancer through ROC analysis (MedCalc program, Valgye). As a result, the sensitivity for diagnosing colorectal cancer was 89.4% (42/47) and the specificity was 93.8% (1/16) (FIG. 2).
  • genomic DNA was isolated from the sera of 13 colorectal cancer patients and 6 normal subjects to determine whether SDC2 gene methylation was detected in serum samples of colorectal cancer patients.
  • the isolated genomic DNA was converted to bisulfite using the EZ DNA Methylation Gold kit (Zymo Research) according to the manufacturer's instructions and eluted with final 10 uL of distilled water.
  • methylation was measured in the same manner as above using the methylation specific primers and probes of set 808.
  • CT values were used to assess sensitivity and specificity for the diagnosis of colorectal cancer through ROC analysis (MedCalc program, Belgium). As a result, the sensitivity for the diagnosis of colorectal cancer was excellent at 84.6% (11/13) and specificity at 100% (0/6) (FIG. 3).
  • the methylation detection method of the SDC2 gene CpG island region According to the methylation detection method of the SDC2 gene CpG island region according to the present invention, it is possible to detect methylation of the SDC2 gene CpG island region with a high detection rate in clinical samples, and to accurately and quickly and efficiently efficiently methylate the SDC2 gene CpG island region. Can be detected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne : un procédé de détection de la méthylation d'une région d'îlot CpG d'un gène syndécane 2 (SDC2) ; une composition pour détecter la méthylation d'une région d'îlot CpG d'un gène SDC2 ; et un kit pour détecter la méthylation d'une région d'îlot CpG d'un gène SDC2 et, plus particulièrement : un procédé de détection de la méthylation d'une région d'îlot CpG d'un gène SDC2 par amplification de l'ADN de SDC2 méthylé à l'aide d'une amorce sens et/ou d'une amorce antisens, qui se lie de manière complémentaire à l'ADN de SDC2 méthylé et qui comprend au moins un CG et/ou GC ; une composition pour détecter la méthylation d'une région d'îlot CpG d'un gène SDC2, contenant l'amorce ; et un kit pour détecter la méthylation d'une région d'îlot CpG d'un gène SDC2, contenant l'amorce.
PCT/KR2018/003415 2017-04-17 2018-03-23 Procédé de détection de méthylation du gène syndécane 2 (sdc2) Ceased WO2018194280A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170049266 2017-04-17
KR10-2017-0049266 2017-04-17

Publications (1)

Publication Number Publication Date
WO2018194280A1 true WO2018194280A1 (fr) 2018-10-25

Family

ID=63856330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003415 Ceased WO2018194280A1 (fr) 2017-04-17 2018-03-23 Procédé de détection de méthylation du gène syndécane 2 (sdc2)

Country Status (1)

Country Link
WO (1) WO2018194280A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110699437A (zh) * 2019-11-11 2020-01-17 益善生物技术股份有限公司 人sdc2基因甲基化检测试剂盒
WO2020256293A1 (fr) * 2019-06-18 2020-12-24 (주)지노믹트리 Procédé de détection de la méthylation du gène sdc2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110084487A (ko) * 2011-07-06 2011-07-25 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
KR20140059125A (ko) * 2012-11-07 2014-05-15 (주)지노믹트리 위용종 및 위암 특이적 메틸화 마커 유전자를 이용한 위용종 및 위암의 검출방법
KR20150114844A (ko) * 2014-04-02 2015-10-13 (주)지노믹트리 이노신 함유 변형 프라이머를 이용한 바이설파이트 처리에 의해 변환된 dna의 메틸화 검출방법
KR20160041905A (ko) * 2013-08-14 2016-04-18 (주)지노믹트리 전암병변의 검출방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110084487A (ko) * 2011-07-06 2011-07-25 (주)지노믹트리 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법
KR20140059125A (ko) * 2012-11-07 2014-05-15 (주)지노믹트리 위용종 및 위암 특이적 메틸화 마커 유전자를 이용한 위용종 및 위암의 검출방법
KR20160041905A (ko) * 2013-08-14 2016-04-18 (주)지노믹트리 전암병변의 검출방법
KR20150114844A (ko) * 2014-04-02 2015-10-13 (주)지노믹트리 이노신 함유 변형 프라이머를 이용한 바이설파이트 처리에 의해 변환된 dna의 메틸화 검출방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Hints for Optimizing Bisulfite Primer Design", EPIGENIE WEBSITE, 12 September 2014 (2014-09-12), XP055560236, Retrieved from the Internet <URL:http://epigenie.com/hints-for-optimizing-bisulfite-primer-design> *
LU , J. ET AL.: "PrimerSuite: a High-throughput Web-based Primer Design Program for Multiplex Bisulfite PCR", SCIENTIFIC REPORTS, vol. 7, no. 1, 24 January 2017 (2017-01-24), pages 1 - 12, XP055560239 *
THOMASSIN, H. ET AL.: "MethylQuant: a Sensitive Method for Quantifying Methylation of Specific Cytosines within the Genome", NUCLEIC ACIDS RESEARCH, vol. 32, no. 21, 2 December 2004 (2004-12-02), pages 1 - 9, XP055560238 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020256293A1 (fr) * 2019-06-18 2020-12-24 (주)지노믹트리 Procédé de détection de la méthylation du gène sdc2
KR20200144287A (ko) * 2019-06-18 2020-12-29 (주)지노믹트리 Sdc2 유전자의 메틸화 검출방법
KR102280363B1 (ko) * 2019-06-18 2021-07-22 (주)지노믹트리 Sdc2 유전자의 메틸화 검출방법
JP2022537540A (ja) * 2019-06-18 2022-08-26 ゲノミックツリー インコーポレイテッド Ｓｄｃ２遺伝子のメチル化検出方法
EP3992306A4 (fr) * 2019-06-18 2023-11-08 Genomictree, Inc. Procédé de détection de la méthylation du gène sdc2
JP7447155B2 (ja) 2019-06-18 2024-03-11 ゲノミックツリー インコーポレイテッド Ｓｄｃ２遺伝子のメチル化検出方法
US12416042B2 (en) 2019-06-18 2025-09-16 Genomictree, Inc. Method for detecting methylation of SDC2 gene
CN110699437A (zh) * 2019-11-11 2020-01-17 益善生物技术股份有限公司 人sdc2基因甲基化检测试剂盒

Similar Documents

Publication Publication Date Title
WO2014073785A1 (fr) Procédé permettant de détecter les polypes gastriques et le cancer gastrique à l&#39;aide d&#39;un gène marqueur du polype gastrique et de la méthylation spécifique du cancer gastrique
WO2011055916A2 (fr) Procédé de détection de la méthylation de gènes marqueurs de méthylation spécifiques du cancer du côlon pour le diagnostic du cancer du côlon
WO2009113771A1 (fr) Méthode de dépistage du cancer du poumon au moyen de gènes marqueurs de méthylation spécifiques du cancer du poumon
KR101074841B1 (ko) 방광암 특이적 메틸화 마커 유전자를 이용한 방광암 진단용키트 및 칩
WO2012070861A2 (fr) Biomarqueur de méthylation spécifique du cancer de l&#39;estomac pour le diagnostic du cancer de l&#39;estomac
WO2021075797A2 (fr) Composition pour le diagnostic de cancer du foie à l&#39;aide de modifications de la méthylation de cpg dans des gènes spécifiques et son utilisation
WO2014168346A1 (fr) Méthode de dépistage du cancer de la vessie au moyen d&#39;un gène marqueur épigénétique spécifique du cancer de la vessie
WO2015023146A1 (fr) Méthode de détection de lésions précancéreuses
WO2017122896A1 (fr) Marqueur génétique servant à distinguer et à détecter le virus responsable d&#39;une maladie infectieuse touchant les poissons marins, et procédé de distinction et de détection du virus causal utilisant le marqueur
WO2018169145A1 (fr) Système de prédiction de pronostic post-chirurgie ou de compatibilité vis-à-vis de médicaments anticancéreux de patients atteints d&#39;un cancer gastrique avancé
WO2012081928A2 (fr) Procédé pour la détection de la méthylation du gène gpm6a marqueur de méthylation spécifique au cancer des intestins en vue du diagnostic du cancer des intestins
WO2012023648A1 (fr) Composition de diagnostic pour le cancer des poumons non à petites cellules comprenant une préparation pour mesurer le taux de méthylation du gène hoxa11 et un procédé de diagnostic pour le cancer des poumons non à petites cellules utilisant la même
WO2024080731A1 (fr) Gènes marqueurs de méthylation pour le diagnostic du cancer du pancréas et leur utilisation
WO2023063562A1 (fr) Gène marqueur de méthylation pour le diagnostic du cancer colorectal à l&#39;aide d&#39;adn acellulaire et son utilisation
EP3904516A1 (fr) Marqueur tumoral basé sur une modification de méthylation stamp-ep6
EP2402461A1 (fr) Méthode et kit pour la détection de chondrocytes par deméthylation des gènes spécifiques
WO2021154009A1 (fr) Composition utilisant des changements de méthylation cpg dans des gènes spécifiques pour diagnostiquer le cancer de la vessie, et son utilisation
WO2018194280A1 (fr) Procédé de détection de méthylation du gène syndécane 2 (sdc2)
WO2011132989A2 (fr) Marqueur de méthylation pour le diagnostic du cancer cervical
WO2024043743A1 (fr) Composition pour l&#39;amplification du gène flt3 et ses utilisations
WO2021118288A1 (fr) Procédé pcr et kit pcr pour augmenter la discrimination allélique
WO2022075788A1 (fr) Composition pour diagnostiquer un cancer colorectal, un cancer rectal ou un adénome colorectal à l&#39;aide d&#39;un changement de méthylation cpg du gène linc01798, et son utilisation
US10907203B1 (en) DNA methylation assays for body fluid identification
EP1748080A2 (fr) L&#39;ADN spécifique pour la caractérisation epigénétique de cellules et tissus
WO2023132626A1 (fr) Composition pour diagnostiquer le cancer de la prostate en utilisant les changements de methylation des gènes cpg dans des gènes specifiques, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18787156

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18787156

Country of ref document: EP

Kind code of ref document: A1